ImmuCell — Q3 2026 Earnings Summary

Financial Performance

• Total sales for the three months ended September 30, 2026, were $8.0 million, representing a 46.0% increase compared to the same period in 2025.
• Domestic sales for the three months ended September 30, 2026, were $6.9 million, a 29.2% increase compared to 2025.
• Total sales for the nine months ended September 30, 2026, were $25.6 million, a 27.8% increase compared to the nine months ended September 30, 2025.
• The press release does not provide data on earnings, profit margins, cash flow, deferred revenue, or debt.

Business Segments and Product Lines

• Third-quarter growth was broad-based across the product portfolio.
• Tri-Shield® sales grew 51% compared to the third quarter of 2025.
• Dual-Force® sales grew 36% compared to the third quarter of 2025.
• The recently launched functional feed line grew 37% compared to the third quarter of 2025.
• Growth was attributed to sales team expansion, improved commercial execution, and the ability to reliably manufacture product to meet customer demand.

Management Commentary and Tone

• CFO Timothy Fiori expressed pleasure with the sales results, noting that comparative growth was aided by depressed sales levels in Q3 2025 caused by high distributor purchases in Q2 2025.
• President and CEO Olivier te Boekhorst stated that third-quarter growth reflects the results of sales team expansion and continuous improvements in commercial execution.
• Management announced a decision to discontinue early sales reporting to align with standard SEC reporting practices, with future revenue and full financial metrics to be reported at regular quarterly events.

Other Key Points

• ImmuCell will host a conference call on Friday, November 13, 2026, at 9:00 AM ET to discuss unaudited financial results for the quarter and nine months ended September 30, 2026.
• The company operates in the animal health biologics market, specifically focusing on calf health solutions and the First Defense® line of products.
• A teleconference replay will be available until November 20, 2026.
• The press release includes a standard Cautionary Note regarding forward-looking statements and risks related to competition, customer acceptance, production capacity expansion, and order timing.